Introduction
Solider 10 is a muscarinic antagonist that is used in the treatment of overactive bladder. It relieves urinary symptoms like frequent urination, urgent need to urinate and inability to control urination.
Solider 10 is advised to take it in a dose and duration as per prescription. It can be taken with or without food. Swallow the medicine as a whole without crushing or chewing it. You should not stop taking the medicine without consulting the doctor as it may lead to the worsening of your symptoms. The course of the treatment should be completed for better efficacy of the medicine.
Some common side effects of this medicine are dry mouth, constipation, nausea, and urinary tract infection. To avoid or cope up with the side effects, you must drink plenty of water. It may also lead to blurry vision or dizziness, so it is advised to avoid driving while on the medication.
Before receiving the treatment, inform your doctor if you are on any medication for any other health condition. If you are pregnant or breastfeeding, tell your doctor prior to the treatment. Patients with liver or kidney disease must be cautious while receiving the prescription, and they must receive regular follow-ups as per the doctor's advice.
Uses of Solider 10
- Overactive bladder (OAB) symptoms
Side effects of Solider 10
Common
- Dryness in mouth
- Constipation
- Blurred vision
- Nausea
- Upset stomach
- Urinary tract infection
How to use Solider 10
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Solider 10 may be taken with or without food, but it is better to take it at a fixed time.
How Solider 10 works
Solider 10 is an antimuscarinic. It works by relaxing muscles of the urinary bladder to prevent frequent, urgent or uncontrolled urination.
What if you forget to take Solider 10?
If you miss a dose of Solider 10, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Indication
Overactive bladder
Administration
May be taken with or without food. Swallow whole, do not chew/crush.
Adult Dose
Oral
Overactive bladder
Adult: 5 mg once daily. If well tolerated, may increase to 10 mg once daily if needed. For patients who are concurrently taking CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max dose: 5 mg once daily.
Hepatic impairment: Child-pugh class B: Max: 5 mg daily; Child-pugh class C: Use is not recommended.
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<30 Max: 5 mg daily.
Contraindication
Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.
Mode of Action
Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure.
Precaution
Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.
Side Effect
Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza.
Interaction
May interfere with the prokinetic effects of cisapride and metoclopramide.
Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride.
Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.